Chief Executive Officer Cameron Reynolds described the move as a strategic step toward strengthening the firm's balance sheet. By retiring the debt early, Volition aims to minimize the impact of convertible instruments on its stock structure while prioritizing broader expense reduction. The company maintains its focus on developing diagnostic blood tests for cancer and diseases associated with NETosis.

While the primary note is settled, Volition still carries a separate $2.4 million obligation to Lind issued in January 2026. According to company filings, the outstanding balance on that secondary note currently sits at approximately $2,041,667. Management continues to signal that further debt restructuring remains a core objective for the remainder of the fiscal year.